h11B6-based radioimmunotherapeutic (Diaprost/Janssen)

N/A

Report date: 2025/11/21 17:15:21

Base Information

Drug Nameh11B6-based radioimmunotherapeutic (Diaprost/Janssen)

Drug Alias Nameanti-hk2 antibody-based therapeutic radiopharmaceutical (Janssen/Diaprost)radiolabeled humanized human kallikrein 2 antibody (Diaprost/Janssen)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionKallikrein 2 modulators

TargetsKallikrein 2

Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDiaprost

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesDiaprost

Active IndicationsHormone-Resistant Prostate Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A